Gilead says shorter remdesivir regimen is effective and drug met main goal in government study – MarketWatch

Gilead Sciences Inc. GILD, +3.80% on Wednesday morning announced data from two clinical trials testing its experimental drug remdesivir in severely ill COVID-19 patients. The drugmaker’s stock was halted in premarket trading on Wednesday in advance of company disclosures about remdesivir’s performance in the studies. Gilead said an open-label Phase 3 trial testing the therapy in severely ill patients found that those taking a 5-day or 10-day course of treatment led to similar results. At least 52% of participants taking either dosing regimen were discharged from the hospital after 14 days of treatment, and at least 53% of those patients were reported as reaching “clinical recovery.” “Multiple concurrent studies are helping inform whether remdesivir is a safe and effective treatment for COVID-19,” Gilead chief medical officer Merdad Parsey said in a statement. “The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir.” Source: Gilead says shorter remdesivir regimen is effective and drug met main goal in government study – MarketWatch